What to Know About GLP-1 Medications and Weight Management Programs
Learn how Eden connects patients to licensed providers to explore GLP-1 medications as part of medical weight management programs.
Struggling with semaglutide constipation? Learn what causes it, how long it can last, and simple steps to support digestion and regularity.
Semaglutide is a GLP-1 receptor agonist prescribed under brand names like Ozempic®, Rybelsus®, and Wegovy® for FDA-approved uses related to type 2 diabetes and weight management. As interest in GLP-1 medications grows, so do questions about gastrointestinal side effects, including constipation reported in some individuals using semaglutide..
In this article, we explore why constipation may occur with semaglutide and what strategies may support digestive comfort.
GLP-1 receptor agonists like semaglutide slow the rate at which the stomach empties, which can affect the digestive process. This slower movement may help regulate blood sugar and appetite, but for some individuals, it may also lead to constipation.
Contributing factors include:
Rates vary depending on dose and product. According to available data:
Constipation may improve as the body adjusts to treatment, especially when hydration, fiber intake, and activity levels are maintained.
Speak with a licensed healthcare provider if symptoms are ongoing or interfere with daily life. Medical advice can help determine whether changes to your care plan are appropriate.
The following lifestyle strategies may help ease constipation. These approaches are not guaranteed to resolve symptoms but are commonly used to support general digestive wellness:
Some patients may benefit from short-term use of non-prescription remedies. Always consult a licensed medical provider before using any medication.
These may include:
Overuse of laxatives can lead to dependency or worsening symptoms. Follow a licensed healthcare provider’s recommendations carefully.
Semaglutide constipation can be uncomfortable, but individuals may find improvement with hydration, fiber, consistent routines, and medical guidance when needed. It is important to monitor symptoms and communicate with a provider to ensure appropriate support.
Eden connects individuals with licensed healthcare providers who can evaluate whether GLP-1 treatment may be appropriate based on personal health goals. If prescribed, medications are dispensed by state-licensed pharmacies. ⁴.
This article is for informational purposes only and does not provide medical or legal advice. Eden does not manufacture or dispense medications and does not provide medical services. Eden connects individuals with independent, licensed providers who evaluate eligibility for treatment based on clinical judgment
Disclaimer: The FDA does not approve compounded medications for safety, quality, or manufacturing. Prescriptions and a medical evaluation are required for certain products. The information provided on this blog is for general informational purposes only. It is not intended as a substitute for professional advice from a qualified healthcare professional and should not be relied upon as personal health advice. The information contained in this blog is not meant to diagnose, treat, cure, or prevent any disease. Readers are advised to consult with a qualified healthcare professional for any medical concerns, including side effects. Use of this blog's information is at your own risk. The blog owner is not responsible for any adverse effects or consequences resulting from the use of any suggestions or information provided in this blog.
Constipation is a reported side effect for some people using semaglutide.
In available studies, constipation lasted about 47 days on average, though this varies widely.
Do not stop taking semaglutide without speaking with your provider.
Severe or long-lasting digestive symptoms should be evaluated by a provider. The FDA has noted rare reports of ileus with GLP-1 medications ⁵.
Camilleri, M. (2025). GLP‐1 receptor agonists and retained gastric content: Is it much ado about nothing? Obesity. https://doi.org/10.1002/oby.24215
Cencioni, C., Malatesta, S., Benedetti, V. V., Licursi, V., Perfetto, L., Conte, F., Ranieri, D., Bartolazzi, A., Kunkl, M., Tuosto, L., Larghi, A., Piro, G., Agostini, A., Tortora, G., Corbo, V., Carbone, C., & Spallotta, F. (2025). The GLP-1R agonist semaglutide reshapes pancreatic cancer associated fibroblasts reducing collagen proline hydroxylation and favoring T lymphocyte infiltration. Journal of Experimental & Clinical Cancer Research, 44(1). https://doi.org/10.1186/s13046-024-03263-w
Gorgojo-Martínez, J. J., Mezquita-Raya, P., Carretero-Gómez, J., Castro, A., Cebrián-Cuenca, A., De Torres-Sánchez, A., García-De-Lucas, M. D., Núñez, J., Obaya, J. C., Soler, M. J., Górriz, J. L., & Rubio-Herrera, M. Á. (2022). Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus. Journal of Clinical Medicine, 12(1), 145. https://doi.org/10.3390/jcm12010145
Ito, H., Ito, K., Tanaka, M., Hokamura, M., Tanaka, M., Kusano, E., Kondo, J., Izutsu, T., Matsumoto, S., Inoue, H., Antoku, S., Yamasaki, T., Mori, T., & Togane, M. (2022). Constipation Is a Frequent Problem Associated with Vascular Complications in Patients with Type 2 Diabetes: A Cross-sectional Study. Internal Medicine, 61(9), 1309–1317. https://doi.org/10.2169/internalmedicine.7676-21
Lai, S., Zhu, C., Zhou, X., Zeng, Q., Huang, L., Cao, X., Zhou, Q., Zhong, Y., Huang, J., Liu, J., Zeng, G., & Chen, H. (2024). Effect of physical activity on the association between diet and constipation: evidence from the National Health and Nutrition Examination Survey 2007-2010. Journal of Neurogastroenterology and Motility, 30(3), 322–331. https://doi.org/10.5056/jnm23134
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., Woo, V., Hansen, O., Holst, A. G., Pettersson, J., & Vilsbøll, T. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 375(19), 1834–1844. https://doi.org/10.1056/nejmoa1607141